Jounce Therapeutics, Inc. Contracts & Agreements
33 Contracts & Agreements
- Business Finance (8 contracts)
- Business Operations (3)
- Human Resources (14)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (4)
- Uncategorized (1)
- Lease Termination Agreement, by and between the Company and the Landlord, dated May 2, 2023 (Filed With SEC on May 4, 2023)
- Agreement and Plan of Merger between the Company, Concentra and Merger Sub, dated March 26, 2023 (Filed With SEC on March 27, 2023)
- Form of Restricted Stock Unit Award Agreement Amendment under 2017 Stock Option and Incentive Plan (for employees) (Filed With SEC on March 10, 2023)
- Form of Non-Qualified Stock Option Agreement Inducement Grant for Employees, as amended (Filed With SEC on March 10, 2023)
- First Amendment to Lease Agreement by and between ARE-770/784/790 Memorial Drive, LLC and the Registrant, dated March 21, 2017 (Filed With SEC on March 10, 2023)
- Asset Purchase and License Amendment Agreement by and between the Company and Gilead dated December 27, 2022 (Filed With SEC on December 27, 2022)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 4, 2022)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 2, 2022)
- Sales Agreement, dated as of November 4, 2021, by and between the Company and Cowen and Company, LLC (Filed With SEC on November 4, 2021)
- Form of Non-Qualified Stock Option Agreement Inducement Grant for Employees (Filed With SEC on August 5, 2021)
- Underwriting Agreement, dated March 9, 2021, by and among Jounce Therapeutics, Inc., Cowen and Company, LLC and Piper Sandler & Co., as representatives of the several underwriters... (Filed With SEC on March 10, 2021)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 25, 2021)
- License Agreement by and between the Registrant and Gilead Sciences, Inc., dated as of August 31, 2020 (Filed With SEC on November 6, 2020)
- Stock Purchase Agreement by and between the Registrant and Gilead Sciences, Inc. dated as of August 31, 2020 (Filed With SEC on November 6, 2020)
- Registration Rights Agreement by and between the Registrant and Gilead Sciences, Inc., dated as of August 31, 2020 (Filed With SEC on November 6, 2020)
- Description of Securities (Filed With SEC on February 27, 2020)
- Sales Agreement, dated as of December 17, 2019, by and between the Company and Cowen and Company, LLC (Filed With SEC on December 17, 2019)
- License Agreement by and among the Registrant, Celgene Corporation, and Celgene RIVOT LLC, dated July 22, 2019 (Filed With SEC on November 7, 2019)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 8, 2019)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 13, 2018)
- Form of Restricted Stock Unit Award Agreement under 2017 Stock Option and Incentive Plan (for employees) (Filed With SEC on August 9, 2018)
- 2017 Employee Stock Purchase Plan, As Amended (Filed With SEC on November 13, 2017)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 13, 2017)
- LEASE TERMINATION AGREEMENT (Filed With SEC on May 23, 2017)
- SUBLEASE TERMINATION AGREEMENT (Filed With SEC on May 23, 2017)
- Jounce Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 10, 2017)
- JOUNCE THERAPEUTICS, INC. 2017 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on January 17, 2017)
- JOUNCE THERAPEUTICS, INC. 2017 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on January 17, 2017)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on January 17, 2017)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on January 17, 2017)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on January 17, 2017)
- JOUNCE THERAPEUTICS, INC. FORM OF OFFICER INDEMNIFICATION AGREEMENT (Filed With SEC on January 17, 2017)
- JOUNCE THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN (Filed With SEC on January 17, 2017)
